AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Drugdiscoverynews

Published November 13, 2026 · Updated November 14, 2026

Five labs fail to replicate therapeutic effects of psilocybin in mice | Drug Discovery News

Read the full story at Drugdiscoverynews

“It's an urgent call to the field,” Lammel said in the press release . “It means, hey, we understand the excitement about psychedelic drugs and we.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic press release